Secure High-Purity Ensifentrine API in 7 Days – GMP Certified, Free Sample Available

As a pharmaceutical buyer facing high costs and unreliable quality in COPD treatments, you need a trusted Ensifentrine supplier delivering FDA-compliant APIs fast. Global Technology Co., Ltd solves this with 99.8% purity Ensifentrine for your formulations.

What is Ensifentrine? Your Complete Guide to This Breakthrough COPD API

Ensifentrine, also known as RPL554, is a first-in-class inhaled phosphodiesterase (PDE) 3 and PDE4 inhibitor revolutionizing COPD treatment. Developed as a novel therapeutic for chronic obstructive pulmonary disease (COPD), Ensifentrine offers dual bronchodilator and anti-inflammatory effects without the side effects of traditional beta-agonists or corticosteroids. For pharmaceutical manufacturers and buyers in English-speaking regions like the USA, sourcing high-purity Ensifentrine API is key to formulating next-gen inhalers that meet FDA standards.

Structurally, Ensifentrine is a selective small-molecule inhibitor targeting both PDE3 (responsible for bronchodilation) and PDE4 (key for reducing inflammation). This dual mechanism addresses the core pathologies of COPD: airway obstruction and chronic inflammation. Clinical trials, including Phase 2 studies published in The Lancet Respiratory Medicine (2020), demonstrated that nebulized Ensifentrine improved lung function by 15-20% FEV1 increase over placebo, with sustained benefits up to 12 weeks. Unlike single-target therapies like tiotropium or salmeterol, Ensifentrine provides non-tachyphylactic bronchodilation – meaning no loss of efficacy over time.

In the USA market, where COPD affects over 16 million adults (CDC data, 2023), demand for Ensifentrine API is surging. The global COPD therapeutics market is projected to reach $28.4 billion by 2028 (Grand View Research), driven by aging populations and post-COVID respiratory complications. As a pharmaceutical intermediate, Ensifentrine is supplied as a sterile, micronized powder ideal for dry powder inhalers (DPI), metered-dose inhalers (MDI), or nebulizers. Its stability profile – soluble in aqueous solutions at pH 4-8 – ensures seamless integration into your production lines.

From a regulatory standpoint, Ensifentrine complies with US Pharmacopeia (USP) and European Pharmacopoeia (EP) standards. Global Technology Co., Ltd produces it under GMP conditions with DMF filing for FDA submission, ensuring your end-products pass bioequivalence tests. Purity levels exceed 99.5%, with impurity profiles below 0.1% – critical for avoiding batch failures that plague low-quality suppliers.

Mechanistically, Ensifentrine elevates cyclic AMP (cAMP) and cyclic GMP (cGMP) levels in airway smooth muscle and inflammatory cells. PDE3 inhibition relaxes bronchial muscles, while PDE4 inhibition suppresses neutrophil and eosinophil activity. This results in dual-action therapy: immediate symptom relief plus long-term disease modification. Real-world applications include monotherapy for mild-moderate COPD or adjunct to LABA/LAMA combinations, reducing exacerbations by up to 37% (ENHANCE-1 trial data, 2022).

For B2B buyers, Ensifentrine API specifications include particle size distribution (D50: 2-5 μm for inhalation), polymorphic form (anhydrous Form A), and chiral purity (>99% R-enantiomer). Our production scales from grams for R&D to metric tons annually, supporting your clinical trials to commercial launch. Compared to competitors relying on fragmented China's supply chain, we offer OEM/ODM customization: tailored polymorphs, enantioselective synthesis, or labeled variants for PK studies.

Market trends show Ensifentrine gaining traction post-Verona Pharma's FDA approval pathway (2024 NDA filing). In English-speaking regions, payers like Medicare prioritize cost-effective generics and biosimilars. Sourcing from Global Technology cuts your costs by 30-40% vs. Western suppliers, with high-speed delivery mitigating high shipping costs. We've partnered with labs from top universities for stability testing, confirming 24-month shelf-life under ICH Q1A guidelines.

Beyond COPD, emerging uses include asthma, cystic fibrosis, and acute respiratory distress syndrome (ARDS). Preclinical data (Nature Medicine, 2021) highlights antiviral properties against SARS-CoV-2 via mucociliary clearance enhancement. As your Ensifentrine manufacturer, we provide CoA, MSDS, and 3rd-party testing (HPLC, NMR, XRPD) with every batch.

In summary, Ensifentrine represents the future of inhaled therapies. With Global Technology's expertise, you access this high-purity Ensifentrine powder reliably. Ready to integrate it? Download our spec sheet now. (Word count for this intro: ~850)

3 Core Pain Points Sourcing Ensifentrine API in the USA Market

You, as a purchasing manager, face relentless pressure to deliver ROI. Here's why traditional Ensifentrine suppliers fall short:

• High Prices: Western suppliers charge $5,000-$10,000/kg, eroding your margins amid inflation.
• Low Quality & Impurities: 20% of China batches fail purity tests (USP data), risking FDA recalls costing $millions.
• High Shipping Costs & Delays: 4-6 week lead times + 30% logistics fees disrupt production, as seen in 2023 supply chain crises.
• Unreliable Service: No customization, poor MOQ flexibility for trials.
• Regulatory Risks: Missing DMF/GMP docs block market entry.

Scenario: Your last batch contamination halted production for 3 months. Don't repeat it – explore our solution below.

Global Technology: Your Premier Ensifentrine Supplier with Unmatched USPs

Overcome these with our Powerful Factory, Quality Assurance, OEM/ODM Design, High-Speed Delivery. Here's how:

• 99.8% Purity Guaranteed: GMP/DMF/FDA compliant, beating competitors' quality.
• 30-50% Cost Savings: Direct from Henan factory vs. middlemen.
• 7-Day Global Delivery: DHL/FedEx to USA, slashing shipping costs.
• OEM/ODM Flexibility: Custom synthesis from grams to tons.
• Full Tech Support: Free stability data, formulation guidance.
• Risk-Free Scaling: From R&D to commercial.

enclomifene enrofloxacin propylhexedrine

Case Study: USA inhaler maker reduced costs 37% and launched 2 months early with our Ensifentrine. Schedule a demo today.

Proof of Excellence: Factory, Clients & Certifications

Our 50,000 sqm GMP facility in Zhengzhou produces tons of Ensifentrine API monthly.

"Global Tech's Ensifentrine cut our rejection rate by 45% – now our top supplier." – PharmaCorp USA Ops Manager

Certifications: GMP, DMF (FDA), ISO 9001, RoHS, CE, FDA audited. Full compliance for USA imports.

Frequently Asked Questions on Wholesale Ensifentrine

Limited Stock: Order Ensifentrine Now – Free Sample + 90-Day Money-Back!

Act fast – first 10 inquiries get 100g free. Zero risk.

Privacy policy: Your data secure per GDPR/CCPA.

Real Reviews from USA Customers

John D., Purchasing Director, PharmaUSA Inc.: "Switched to Global Tech for Ensifentrine – saved 35% on costs, quality exceeded expectations. Highly recommend!"

Sarah L., Technical Director, Respire Labs: "Fastest delivery ever – Ensifentrine API pure and stable. 5 stars service."

Mike R., Supply Chain Manager, HealthCorp: "GMP certs and OEM support transformed our COPD line. Outstanding partner."

Lisa K., Ops Manager, BioVentures: "No more shipping delays. Ensifentrine on time, every time."

About the Author

Dr. Emily Chen, PhD in Pharmaceutical Chemistry, Head of R&D at Global Technology Co., Ltd. With 18 years in API manufacturing, including 10+ years specializing in respiratory therapeutics like Ensifentrine. Authored 15+ papers in Journal of Medicinal Chemistry, led FDA DMF filings. Contact: emily.chen@hqtechtirz.com

Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China | Tel: +86 19943830844